Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to control Hard-to-Treat blood cancers

NCT ID NCT07284927

Recruiting now Disease control Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or stopped responding to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection and are monitored for side effects and how their body handles it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA NON-HODGKIN LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.